HC Wainwright Issues Pessimistic Outlook for AKBA Earnings

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Research analysts at HC Wainwright decreased their Q2 2026 earnings per share estimates for shares of Akebia Therapeutics in a report issued on Friday, February 6th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will post earnings per share of $0.02 for the quarter, down from their previous forecast of $0.04. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.05 EPS, FY2026 earnings at $0.12 EPS, FY2029 earnings at $0.30 EPS and FY2030 earnings at $0.44 EPS.

Several other equities analysts have also weighed in on AKBA. Piper Sandler reduced their price objective on Akebia Therapeutics from $6.00 to $4.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Akebia Therapeutics in a research report on Wednesday, January 21st. BTIG Research reiterated a “buy” rating and set a $5.00 price target on shares of Akebia Therapeutics in a research note on Tuesday, December 2nd. Finally, Wall Street Zen cut Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $5.60.

Akebia Therapeutics Stock Up 0.7%

Akebia Therapeutics stock opened at $1.51 on Monday. The firm has a 50 day moving average price of $1.52 and a 200-day moving average price of $2.30. The company has a quick ratio of 1.80, a current ratio of 1.94 and a debt-to-equity ratio of 1.15. Akebia Therapeutics has a twelve month low of $1.30 and a twelve month high of $4.08. The company has a market capitalization of $400.71 million, a P/E ratio of -21.57 and a beta of 0.38.

Insider Activity

In related news, CAO Richard C. Malabre sold 49,524 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.39, for a total transaction of $68,838.36. Following the sale, the chief accounting officer owned 299,390 shares of the company’s stock, valued at approximately $416,152.10. This represents a 14.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Akebia Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its position in shares of Akebia Therapeutics by 166.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,706,437 shares of the biopharmaceutical company’s stock valued at $7,577,000 after acquiring an additional 2,938,624 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in Akebia Therapeutics by 39,976.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 299,771 shares of the biopharmaceutical company’s stock worth $483,000 after acquiring an additional 299,023 shares during the period. Geode Capital Management LLC lifted its stake in Akebia Therapeutics by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 6,277,177 shares of the biopharmaceutical company’s stock worth $10,108,000 after purchasing an additional 92,226 shares in the last quarter. Empirical Asset Management LLC boosted its holdings in Akebia Therapeutics by 75.0% in the 4th quarter. Empirical Asset Management LLC now owns 35,000 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 15,000 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Akebia Therapeutics in the 4th quarter valued at $137,000. 33.92% of the stock is currently owned by institutional investors.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.